Skip to main content

Table 1 In vitro susceptibility to standard antimalarial drugs of the multidrug-resistant isolate in comparison with P.falciparum W2 clone and P. falciparum isolates tested with the same plate batches

From: Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia

Drugs

Isolate

IC50

Ratio IC50 Isolate/W2

W2*

IC50

Isolates**

Mean IC50 (CI95%)

Ratio IC50 Isolates/W2

Resistance

cut-off

Dihydroartemisinin

21.2 nM

11.8

1.8 nM

2.2 nM (1.3-3.7)

1.2

> 10.5 nM

Artesunate

16.3 nM

10.2

1.6 nM

1.9 nM (1.0-3.2)

1.2

> 10.5 nM

Quinine

1131 nM

1.5

731 nM

201 nM (131-307)

0.3

> 800 nM

Mefloquine

166 nM

4.5

36.6 nM

26.0 nM (15.9-42.5)

0.7

> 30 nM

Lumefantrine

114 nM

4.0

28.4 nM

23.9 nM (14.1-40.8)

0.8

> 150 nM

Pyronaridine

70.5 nM

7.8

9.0 nM

26.2 nM (15.4-44.6)

2.9

ND

Piperaquine

91.1 nM

3.3

27.3 nM

66.2 nM (34.7-126.3)

2.4

ND

Chloroquine

63 nM

0.14

449 nM

63 nM (29-138)

0.1

> 100 nM

Monodesethylamodiaquine

34.4 nM

0.54

63.2 nM

32.4 nM (19.2-54.8)

0.5

> 80 nM

Atovaquone

2.21 nM

0.74

2.99 nM

1.48 nM (1.06-2.07)

0.5

> 490 nM

Doxycycline

18.5 μM

1.5

12.1 μM

10.0 μM (7.8-12.9)

0.8

> 35 μM

Pyrimethamine

497 nM

0.04

12621 nM

107 nM (7-1681)

0.01

> 2000 nM

  1. * The laboratory-adapted clone W2, tested on the same day, was used as a reference.
  2. ** Values are geometric mean and 95% confidence interval of 16 isolates from imported malaria, tested on the same batch of plates, and used as comparators.
  3. ND: not determined